Annual breast cancer (BCa) deaths have declined since its apex in 1989 concomitant with
widespread adoption of hormone therapies that target estrogen receptor alpha (ERα), the …

Resistance to endocrine treatments and CDK4/6 inhibitors is considered a near-inevitability
in most patients with estrogen receptor positive breast cancers (ER+ BC). By genomic and …

Breast cancer is the most frequent female malignant tumor, and the leading cause of cancer
death in women worldwide. The most common subtype of breast cancer is hormone receptor …

Aberrant activation of the forkhead protein FOXA1 is observed in advanced hormone-related
cancers. However, the key mediators of high FOXA1 signaling remain elusive. We …

Endocrine therapies (ET) with cyclin-dependent kinase 4/6 (CDK4/6) inhibition are the
standard treatment for estrogen receptor-α-positive (ER+) breast cancer, however drug …

The advancements in the detection and characterization of circulating tumor DNA (ctDNA)
have revolutionized precision medicine and are likely to transform standard clinical practice …

Patient-derived organoid models of estrogen receptor-positive (ER+) breast cancer would
provide a much-needed tool to understand drug resistance and disease progression better …

Transcriptionally active ESR1 fusions (ESR1-TAF) are a potent cause of breast cancer
endocrine therapy (ET) resistance. ESR1-TAFs are not directly druggable because the C …

Breast cancer is a leading cause of female mortality and despite advancements in
personalized therapeutics, metastatic disease largely remains incurable due to drug …

In hormone receptor-positive metastatic breast cancer (HR+ MBC), endocrine resistance is
commonly due to genetic alterations of ESR1, the gene encoding estrogen receptor alpha …